Spectris (SXS) Q4 2024 earnings summary

Executive summary

• 2024 saw a 7% like-for-like sales decline amid subdued markets, but strategic actions, including three high-quality acquisitions (Micromeritics, SciAps, Piezocryst), record new product launches, and a Profit Improvement Programme targeting £50m by 2026, led to a strong Q4 and profit slightly ahead of revised guidance.

• Portfolio rationalization completed with the sale of Red Lion Controls, generating £1.3 billion in proceeds and over £1 billion returned to shareholders since 2019.

• Vitality Index rose from 22% to 29% in a record year for new product launches.

• Focus remains on cash generation, deleveraging, and integrating acquisitions to support medium-term targets.

Financial highlights

• Like-for-like order intake down 3% year-over-year, with Q4 seeing 6% order growth and demand stabilization.

• Adjusted operating profit was £202.6 million (down 20% LFL), with a 15.6% margin; statutory operating profit £97.6 million.

• Gross margin declined to 55.1%; adjusted EPS 148.1p (down 26%); cash conversion at 88%; net debt at year-end was £549 million, leverage at 2.3x.

• Dividend per share increased by 5% to 83.2p, marking 35 consecutive years of growth.

• £18.3 million restructuring costs, £16.2 million M&A-related costs, £45 million software implementation costs, and a £210 million gain on Red Lion Controls disposal.

Outlook and guidance

• 2025 expected to deliver significant profit growth, with adjusted operating profit in line with market expectations and a focus on integration, cost synergies, and operational leverage.

• Profit Improvement Programme to deliver £30 million in 2025 and £50 million by 2026, targeting at least 20% margins by 2027.

• Medium-term targets reaffirmed: organic sales growth of 6-7%, adjusted operating margin above 20%, and ROGCE in mid-teens by 2027.

• Cautious macro outlook, but order book and Q4 momentum support confidence in progressive recovery.